Resolution Therapeutics continued to build momentum this week around its EMERALD Phase I/II trial of RTX001, a first-in-class regenerative macrophage therapy for end-stage liver disease. The company reiterated the high unmet need in chronic liver failure and confirmed that the EMERALD interim analysis cohort is now fully recruited across 15 sites in the U.K. and Spain.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CEO Amir Hefni indicated that an interim data readout is targeted for the end of Q3 2026, offering improved visibility into upcoming clinical milestones. The broad study footprint, spanning eight NHS hospitals in the U.K. and seven sites in Spain, underscores Resolution’s early clinical scale and engagement with leading liver centers.
In parallel with trial progress, Resolution appointed Louise Rowe as Vice President of Operations, adding more than 30 years of drug development and commercialization experience. Rowe previously helped advance AVB 101 at AviadoBio through IND clearance and FDA Fast Track designation and led Libmeldy at Orchard Therapeutics to European marketing authorization.
The new hire is positioned to support EMERALD’s execution and potential later-stage development, including complex multi-site operations in the U.K. and Spain. Her background in cell and gene therapies may help the company navigate regulatory pathways and prepare for potential future commercialization if RTX001 delivers positive data.
RTX001 and the EMERALD program also received sector recognition with the “Best Therapeutic R&D Programme of the Year” award at the 2026 One Nucleus Awards. While such accolades do not alter clinical risk, they can enhance the company’s visibility among partners and investors as key data milestones approach.
Resolution further expanded its scientific and policy profile through a BioCentury feature, a Drug Discovery World podcast, and briefings with U.K. health policymakers at Edinburgh BioQuarter. At the Advanced Therapies conference in London, the company highlighted CMC, AI- and automation-enabled manufacturing, and supply chain capabilities, signaling early planning for scalability as its pipeline advances.
Collectively, the week’s developments point to solid clinical execution, a strengthening leadership team, and growing external recognition for Resolution Therapeutics. These factors may improve the company’s positioning ahead of the EMERALD interim readout and support future partnership and financing discussions.